Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on June 7, 2016, covering events that occurred on June 1, 2016. The filing details executive compensation adjustments and the results of the Company's annual meeting of stockholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to executive compensation:
- Stock Option Grant: CEO John M. Gill received an option to purchase 100,000 shares at an exercise price of $2.20 per share.
- Cash Bonus: CEO John M. Gill was awarded a discretionary cash bonus of $25,000.
Material Changes and Corporate Actions
The report highlights two primary corporate actions:
- Executive Compensation: The Board granted a new stock option to the CEO with a 3-year vesting schedule (25% immediate, 25% annually thereafter) expiring May 31, 2026, alongside a cash bonus.
- Director Elections: Stockholders voted to re-elect six directors: John M. Gill, Eric I. Richman, Jeffrey W. Runge, Mitchel B. Sayare, Derace L. Schaffer, and Steven St. Peter. All received significant "For" votes (approx. 30.1 million each) with minimal votes withheld.
Guidance, Outlook, and Voting Results
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It reports the following stockholder voting outcomes:
- Tax Benefit Preservation Plan: Ratified with 30,806,349 votes "For" versus 255,829 "Against".
- Appointment of Auditors: Ratified the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2015, with 51,666,301 votes "For" versus 374,843 "Against".
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Confirm the vesting terms and acceleration clauses of the CEO's new stock option grant.
- Review the Tax Benefit Preservation Plan details to understand how it protects net operating loss carryforwards.
- Check subsequent filings for the impact of the $25,000 cash bonus and stock option on the company's cash position and equity dilution.